A Phase 2 Study of Entospletinib in NPM1 mutant/FLT3 ITD
Wild Type AML Patients Age > 60 years
The purpose of this study is to determine the safety and acceptability of the experimental drug, entospletinib (ENTO, GS-9973), alone and in combination with standard Chemotherapy (Cohort A) or alone and in combination with Azacitidine (Aza, Vidaza) (Cohort B), that is approved by the US Food and Drug Administration (FDA) for MDS (a pre-leukemic condition) as well as a subset of AML subjects.
Acute Myeloid Leukemia (AML)
-Participating in the Beat AML umbrella study master protocol (reference IRB# 16475)
-Newly diagnosed with AML
-Age 60 years or older at time of diagnosis
-An NPM1 mutation but FLT3 ITD negative
60 - n/a
Healthy Volunteers Needed
Duration of Participation
Study participation may include up to 5 years of study drug treatment and an additional 5 years after you stop taking the study drug for follow-up.
Clinical Trials Information Line
Beat AML, LLC, a division of the Leukemia and Lymphoma Society, Inc
Supported by: Gilead Pharmaceuticals